NCT07238322Completed
[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
An Assessment of the Efficacy of Floretyrosine F 18 ([18F]FET) Positron Emission Tomography (PET) for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
Source: ClinicalTrials.gov · Last updated 15 May 2026
Brief summary (registry, in English)
This study is designed to prospectively analyze \[18F\]FET PET image data obtained retrospectively in the routine clinical care of glioma patients. The study will analyse the data from participants with grade (1-4) glioma after primary treatment according to local clinical practice and with suspicion of progression/recurrence on magnetic resonance imaging (MRI).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 253 (actual)
- First submitted
- 1 Oct 2025
- Start date
- Sept 2025
- Primary completion date
- Jan 2026
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Diseases
- Childhood cancers
- NCT number
- NCT07238322
What you commit to
- Study type: Observational
- Participants enrolled: 253
- From Sept 2025 to the primary completion date, Jan 2026
- 4 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Participants will be excluded if they did not meet any of the inclusion criteria or institutional requirements for participation.
- Did not meet all inclusion criteria.
- Did not undergo \[18F\]FET PET imaging as part of routine clinical care.
- Imaging data or associated clinical information is incomplete, non-evaluable, or of insufficient quality for analysis.
- Any institutional or regulatory requirement that precludes data sharing or inclusion in retrospective research studies.
Who the study is looking for
- Signed patient informed consent with secondary use of data permitted. Pediatric patients (\<18 years of age) will provide assent along with parental/legal guardian /caregiver consent
- Male or Female of any age at the time of \[18F\]FET PET imaging. While there is no age restriction, it is expected that enrollment of patients ≤ 3 years old will be rare due to the very low incidence of glioma in this age group.
- Documented histologic diagnosis or clinical suspicion of glioma (Grades 1-4) based on local clinical assessment.
- Underwent \[18F\]FET PET imaging as part of routine clinical care after completion of primary treatment (surgery, radiation therapy, and/or chemotherapy).
- Evidence of radiographic suspicion of recurrence or progression on MRI at the time of \[18F\]FET PET imaging.
- The adult patient, 18 years of age or older, has received nominal injected dose of 4 to 7 mCi (148 - 259 MBq ) of \[18F\]FET per imaging time point.
- The pediatric patients, 0-17 years old, must have received a pediatric dose adjusted based upon the patient's body weight.
Sex: All
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Essen Coordinator of this site? Confirm its status | Essen | Germany | Unknown status |
| Universityhospital Tuebingen Coordinator of this site? Confirm its status | Tübingen | Germany | Unknown status |
| The University Medical Center Utrecht Coordinator of this site? Confirm its status | Utrecht | Netherlands | Unknown status |
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.